REGENERON – Eylea Sales Add a Sparkle to The Eye!
Despite competition from Genentech/Roche’s Lucentis and Avastin (off-label), Regeneron (REGN) overwhelmed all concerns of a “weak launch” of Eylea (VEGF Trap-Eye, L, partnered with Bayer for Ex-US). The uptake indicates that Physician and Payers choose the cost benefit (overall ~45% cheaper than Lucentis) with equivalent efficacy despite the “Buy-and-Bill” model! Uptake at this pace should entitle Eylea to capture…. Moreover, CEO’s optimism around REGN’s future and pipeline resulted in a gain… For more details, please read our report released on 11th January, 2012 on Regeneron titled “Eylea Sales Add a Sparkle to The Eye!”
COMPANIES MENTIONED
REGENERON
REGENERON
